The Relationship between Hepatic Steatosis, inflammation and insulin Resistance in type 2 Diabetes with Metabolic Imbalance

1. Cleveland E, Bandy A and VanWagner LB. Diagnostic Challenges Of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4) 98-104. DOI:10.1002/cld.716.10.1002/cld.716610363530147867Open DOISearch in Google Scholar

2. Younossi ZM. The Epidemiology Of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4):92-94. DOI:10.1002/cld.710.10.1002/cld.710638594730992797Open DOISearch in Google Scholar

3. Naim A, Scott A. An Update On The Pharmacological Treatment Of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications. Clinical Liver Disease, 2018; 11(4):82-86. DOI:10.1002/cld.708.10.1002/cld.708637031630761212Open DOISearch in Google Scholar

4. Fedchuk L, Nascimbeni F, Pais R, et al. Performance And Limitations Of Steatosis Biomarkers In Patients With Nonalcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 2014; 40(10):1209-1222. DOI:10.1111/apt.12963.10.1111/apt.1296325267215Search in Google Scholar

5. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic Fatty Liver Disease: Evolving Paradigms. World Journal Of Gastroenterology, 2017; 23(36):6571-6592. DOI:10.3748/wjg.v23.i36.6571.10.3748/wjg.v23.i36.6571564328229085206Open DOISearch in Google Scholar

6. Kitade H, Chen G, Ni Y and Ota T. Nonalcoholic Fatty Liver Disease And Insulin Resistance: New Insights And Potential New Treatments. Nutrients, 2017; 9(4):387. DOI:10.3390/nu9040387.10.3390/nu9040387540972628420094Open DOISearch in Google Scholar

7. Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty Liver: A Possible New Target For Type 2 Diabetes Prevention And Treatment. International Journal Of Molecular Sciences, 2013; 14(11):22933-22966. DOI:10.3390/ijms141122933.10.3390/ijms141122933385609924264040Open DOISearch in Google Scholar

8. Franch-Nadal J, Caballeria L, Mata-Cases M, et al. Fatty Liver Index Is A Predictor Of Incident Diabetes In Patients With Prediabetes: The PREDAPS Study. PLOS ONE, 2018; 13(6):e0198327. DOI:10.1371/journal.pone.0198327.10.1371/journal.pone.0198327598353329856820Search in Google Scholar

9. Wallace T, Levy J and Matthews D. Use and Abuse of HOMA Modeling. Diabetes Care, 2004; 27(6):1487-1495. DOI: 10.2337/diacare.27.6.148710.2337/diacare.27.6.148715161807Open DOISearch in Google Scholar

10. “Fatty Liver Index - Mdcalc”. Mdcalc.Com, Available from: https://www.mdcalc.com/fatty-liver-index (accessed at 28 December 2018)Search in Google Scholar

11. “Hepatic Steatosis Index (HSI) Calculator”. Available from: https://www.mdapp.co/hepatic-steatosis-index-hsi-calculator-357/ (accessed at 28 December 2018)Search in Google Scholar

12. “Non-Alcoholic Fatty Liver Disease - Liver Fat Score (NAFLD-LFS) Calculator”. Available from:https://www.mdapp.co/non-alcoholic-fatty-liver-disease-liver-fat-score-nafld-lfs-calculator-358/ (accessed at 28 December 2018)Search in Google Scholar

13. Grigorescu ED, Mihai BM, Lăcătușu CM et al. Relationships between insulin resistance, subclinical inflammation and diastolic dysfunction in type 2 diabetes. Paper presented at the 44th National Congress of the Romanian Society of Diabetes, Nutrition and Metabolic Diseases. 23-26 May 2018, Poiana Brasov, RomaniaSearch in Google Scholar

14. Gábor Firneisz. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol, 2014; 20(27):9072–9089. DOI: 10.3748/wjg.v20.i27.907210.3748/wjg.v20.i27.9072411287825083080Open DOISearch in Google Scholar

15. Bril F and Kenneth C. Management Of Nonalcoholic Fatty Liver Disease In Patients With Type 2 Diabetes: A Call To Action. Diabetes Care, 2017; 40(3):419-430. DOI:10.2337/dc16-1787.10.2337/dc16-178728223446Open DOISearch in Google Scholar

16. Ormazabal V, Nair S, Elfeky O et al. Association between insulin resistance and the development of cardiovsacular disease. Cardiovasc Diabetol, 2018:17-122, DOI: 10.1186/s12933-018-0762-410.1186/s12933-018-0762-4611924230170598Open DOISearch in Google Scholar

17. Frati G, Schirone L, Chimenti I et al. An overview of the inflammatory signalling mechanism in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovascular Research, 2017; 113:378-388.10.1093/cvr/cvx01128395009Search in Google Scholar

18. Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovascular Research, 2017;113:389–398. DOI:10.1093/cvr/cvx01210.1093/cvr/cvx01228395010Open DOISearch in Google Scholar

19. Grigorescu ED, Șorodoc V, Floria M. The Inflammatory Marker hsCRP as a Predictor of Increased Insulin Resistance in Type 2 Diabetics without Atherosclerotic Manifestations. REV.CHIM.(Bucharest), 2019; 70(5):1791-1794.10.37358/RC.19.5.7216Search in Google Scholar

20. Elimam H, Abdulla AM and Taha IM. Inflammatory Markers And Control Of Type 2 Diabetes Mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019; 13(1): 800-804. DOI:10.1016/j.dsx.2018.11.061.10.1016/j.dsx.2018.11.06130641811Open DOISearch in Google Scholar

21. Mantovani A, Pernigo M, Bergamini C, et al. Heart Valve Calcification In Patients With Type 2 Diabetes And Nonalcoholic Fatty Liver Disease. Metabolism, 2015; 64(8):879-887. DOI:10.1016/j.metabol.2015.04.003.10.1016/j.metabol.2015.04.00325957758Search in Google Scholar

22. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction In Patients With Type 2 Diabetes. Diabetes Care, 2011; 35 (2): 389-395. DOI:10.2337/dc11-1820.10.2337/dc11-1820326388422210573Open DOISearch in Google Scholar

23. Tokita Y, Maejima Y, Shimomura, et al. Non-Alcoholic Fatty Liver Disease Is A Risk Factor For Type 2 Diabetes In Middle-Aged Japanese Men And Women. Internal Medicine, 2017; 56(7): 763-771. DOI:10.2169/internalmedicine.56.7115.10.2169/internalmedicine.56.7115545791828381741Open DOISearch in Google Scholar

24. Leoni S, Tovoli F, Napoli L, et al. Current Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: A Systematic Review With Comparative Analysis. World Journal Of Gastroenterology, 2018; 24(30):3361-3373. DOI:10.3748/wjg.v24.i30.336110.3748/wjg.v24.i30.3361609258030122876Open DOISearch in Google Scholar

25. Kahl S, Straßburger K, Nowotny B, et al. Comparison Of Liver Fat Indices For The Diagnosis Of Hepatic Steatosis And Insulin Resistance. Plos ONE, 2014; 9(4):e94059. DOI:10.1371/journal.pone.0094059.10.1371/journal.pone.0094059398606924732091Search in Google Scholar

26. Yadav D, Choi E, Ahn SV, et al. Fatty Liver Index As A Simple Predictor Of Incident Diabetes From The Koges-ARIRANG Study. Medicine, 2016; 95(31):e4447. DOI:10.1097/md.0000000000004447.10.1097/MD.0000000000004447497982727495073Open DOISearch in Google Scholar

27. Sviklāne L, Olmane E, Dzērve Z, et al. Fatty Liver Index And Hepatic Steatosis Index For Prediction Of Non-Alcoholic Fatty Liver Disease In Type 1 Diabetes. Journal Of Gastroenterology And Hepatology, 2017; 33(1):270-276. DOI:10.1111/jgh.13814.10.1111/jgh.1381428464337Open DOISearch in Google Scholar

28. Leite NC. Non-Alcoholic Fatty Liver Disease And Diabetes: From Physiopathological Interplay To Diagnosis And Treatment. World Journal Of Gastroenterology, 2014; 20(26): 8377. DOI:10.3748/wjg.v20.i26.8377.10.3748/wjg.v20.i26.8377409369125024596Open DOISearch in Google Scholar

29. Marjot T, Sbardella E, Moola A, et al. Prevalence And Severity Of Non-Alcoholic Fatty Liver Disease Are Underestimated In Clinical Practice: Impact Of A Dedicated Screening Approach At A Large University Teaching Hospital. Diabetic Medicine, 2017; 35(1):89-98. DOI:10.1111/dme.13540.10.1111/dme.1354029094442Open DOISearch in Google Scholar

30. Byrne CD and Giovanni T. EASL–EASD–EASO Clinical Practice Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: Is Universal Screening Appropriate?. Diabetologia, 2016; 59(6):1141-1144. DOI:10.1007/s00125-016-3910-y.10.1007/s00125-016-3910-y27053232Open DOISearch in Google Scholar